View Older Stories

Mar 30, 2026 09:30AM Leerink Partners Reiterates Outperform Rating on Alumis Inc (ALMS)

Mar 30, 2026 09:27AM Guggenheim Reiterates Buy Rating on Alumis Inc (ALMS)

Mar 30, 2026 09:26AM Baird Reiterates Outperform Rating on Alumis Inc (ALMS)

Mar 30, 2026 07:25AM Alumis (ALMS) Reiterated at Buy by Stifel After AAD Presentation

Mar 30, 2026 06:46AM Alumis Inc (ALMS) PT Lowered to $25 at H.C. Wainwright

Mar 10, 2026 04:05PM Raymond James Starts Alumis Inc (ALMS) at Strong Buy

Feb 24, 2026 04:06PM Stifel Starts Alumis Inc (ALMS) at Buy

Jan 21, 2026 04:15AM Chardan Capital Markets Starts Alumis Inc (ALMS) at Buy

Jan 7, 2026 06:32AM Alumis Inc (ALMS) PT Raised to $32 at Guggenheim

Jan 6, 2026 04:08PM Alumis Inc (ALMS) PT Raised to $32 at Leerink Partners

Jan 6, 2026 01:57PM Alumis Inc (ALMS) PT Raised to $50 at Oppenheimer

Jan 6, 2026 09:18AM Alumis Inc (ALMS) PT Raised to $35 at Baird

Jan 6, 2026 06:58AM Alumis (ALMS) Halted, News Pending

Dec 18, 2025 09:57AM Alumis Inc (ALMS) PT Raised to $20 at H.C. Wainwright

Aug 14, 2025 07:39AM Cantor Fitzgerald Reiterates Overweight Rating on Alumis Inc (ALMS)

Jul 25, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Alumis Inc (ALMS)

Jul 14, 2025 04:05PM Alumis promotes Sanam Pangali to chief legal officer

Jun 10, 2025 06:08AM Guggenheim Resumes Alumis Inc (ALMS) at Buy

May 29, 2025 07:56AM Alumis (ALMS) Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program for ESK-001

May 21, 2025 09:11AM Alumis (ALMS) Completes Merger with ACELYRIN

May 13, 2025 01:00PM Alumis (ALMS) Stockholders Approve Merger with ACELYRIN (SLRN)

May 13, 2025 01:00PM Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS)

May 1, 2025 01:31PM Acelyrin (SLRN) Reiterates Benefits of Value-Maximizing Combination with Alumis (ALMS)

Apr 22, 2025 06:59AM Alumis Inc (ALMS) PT Lowered to $14 at H.C. Wainwright

Apr 21, 2025 06:36AM Alumis (ALMS) and ACELYRIN (SLRN) to Merge

Apr 4, 2025 04:36PM Alumis (ALMS) and Acelyrin (SLRN) file joint proxt statement for merger

Mar 26, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Alumis Inc (ALMS)

Mar 25, 2025 08:38AM Alumis (ALMS) and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 20, 2025 01:42PM Baird Reiterates Outperform Rating on Alumis Inc (ALMS)

Mar 20, 2025 08:06AM Cantor Fitzgerald Reiterates Overweight Rating on Alumis Inc (ALMS)

Mar 20, 2025 06:38AM Alumis Inc (ALMS) PT Lowered to $15 at H.C. Wainwright

Mar 10, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Alumis Inc (ALMS)

Mar 4, 2025 09:05AM Alumis (ALMS) and ACELYRIN (SLRN) Reaffirm Strategic and Financial Rationale of Proposed Merger

Feb 28, 2025 09:09AM Alumis (ALMS) Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001

Feb 27, 2025 04:15PM Alumis (ALMS) Presents Additional Phase 1 Data

Feb 21, 2025 07:21AM Acelyrin (SLRN) Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

Feb 7, 2025 06:48AM Alumis Inc (ALMS) PT Lowered to $19 at H.C. Wainwright

Feb 6, 2025 04:16PM Alumis (ALMS) and ACELYRIN (SLRN) to Merge

Feb 6, 2025 04:15PM Alumis (ALMS) Halted, News Pending

Jan 30, 2025 06:14AM Oppenheimer Starts Alumis Inc (ALMS) at Outperform

Jan 28, 2025 08:05AM Alumis (ALMS) Announces Leadership Changes

Jan 6, 2025 07:09AM H.C. Wainwright Reiterates Buy Rating on Alumis Inc (ALMS)

Dec 19, 2024 08:00AM Alumis (ALMS) Announces Positive Phase 1 Data for A-005

Nov 14, 2024 06:58AM Alumis Inc (ALMS) PT Lowered to $26 at H.C. Wainwright

Oct 30, 2024 04:08PM Baird Starts Alumis Inc (ALMS) at Outperform

Oct 17, 2024 09:22AM H.C. Wainwright Starts Alumis Inc (ALMS) at Buy

Sep 27, 2024 09:00AM Alumis (ALMS) Reports ESK-001 Demonstrated Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Jul 29, 2024 08:04AM Alumis (ALMS) Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 23, 2024 06:31AM Cantor Fitzgerald Starts Alumis Inc (ALMS) at Overweight

Jul 23, 2024 03:27AM Morgan Stanley Starts Alumis Inc (ALMS) at Overweight

View Older Stories